Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

27.86 +1.46 (+5.53%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	540,365
Open	26.60
Bid (Size)	24.86 (100)
Ask (Size)	28.00 (2,300)
Prev. Close	26.40
Today's Range	26.46 - 28.16
52wk Range	5.485 - 32.64
Shares Outstanding	14,410,143
Dividend Yield	69.48%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces New Board Member and Board Transition

December 11, 2025

Appoints accomplished commercial leader Chris Martin to its Board of Directors

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-1.5%	-1.5%
1 Month	-7.8%	-7.8%
3 Month	+9.2%	+9.2%
6 Month	+89.5%	+89.5%
1 Year	+77.2%	+77.2%

More News

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗

September 29, 2025

Via Stocktwits

AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 13, 2025

Via Benzinga

Oruka Therapeutics Inc (NASDAQ:ORKA) Reports Q3 2025 Results, Beats EPS Estimates and Provides Clinical Pipeline Updates ↗

November 12, 2025

Via Chartmill

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

The Insider Report: The Bulls Can Thank Tech ↗

November 02, 2025

Via Benzinga

Oruka Therapeutics to Present at Multiple November Investor Conferences

October 29, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Stock Market Today: Nasdaq, S&P 500 Futures Rise As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus ↗

October 06, 2025

Via Benzinga

Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday ↗

October 05, 2025

Via Benzinga

MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗

September 29, 2025

Via Investor's Business Daily

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Via Chartmill

Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday ↗

September 17, 2025

Via Benzinga

Oruka Therapeutics, Up 20%, Is Trying To Take On AbbVie's Biggest Moneymaker ↗

September 17, 2025

Via Investor's Business Daily

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket ↗

September 17, 2025

Via Benzinga

Oruka Therapeutics Announces $180 Million Private Placement

September 17, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

September 17, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

July 21, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

July 01, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025

From Oruka Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Oruka Therapeutics, Inc. - Common Stock publicly traded?

Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?

Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?

The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market

What is the current price of Oruka Therapeutics, Inc. - Common Stock?

The current price of Oruka Therapeutics, Inc. - Common Stock is 27.86

When was Oruka Therapeutics, Inc. - Common Stock last traded?

The last trade of Oruka Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET

What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?

The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 401.47M

How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?

Oruka Therapeutics, Inc. - Common Stock has 401M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.